Companies Treace Medical Concepts, Inc
Treace Medical Concepts (TMCI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Treace Medical Concepts, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers25th pct.Of 8 peer CEOs
CEO pay, last three years
- $8,422,635FY2023
- $6,597,160FY2024
- $5,405,190FY2025
CEO total pay was $5,405,190 in fiscal 2025, down from $6,597,160 in fiscal 2024.
FY2025: salary $755,353 · bonus $0 · stock awards $4,635,000 · option awards $0
Executives and directors
Gaetano Guglielmino · CCOJohn Treace · CEOMark Hair · CFOScot Elder · General CounselSean Scanlan · Chief Innovation OfficerDeepti Jain · Independent DirectorElizabeth S. Hanna · Independent DirectorJames T. Treace · Former director (through FY2025)Jane E. Kiernan · Independent DirectorJohn K. Bakewell · Lead Independent DirectorLance A. Berry · Independent DirectorLawrence W. Hamilton · Independent DirectorRichard W. Mott · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at Treace Medical Concepts, Inc in fiscal 2025?
As disclosed, John Treace (Chief Executive Officer, Founder and Board Chair) was the highest-paid executive at Treace Medical Concepts, Inc in fiscal 2025, with total compensation of $5,405,190.
How does Treace Medical Concepts, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, John Treace's total compensation ranked at the 25th percentile of Treace Medical Concepts, Inc's disclosed peer group.
What is Treace Medical Concepts, Inc's CEO-to-median employee pay ratio?
As disclosed, Treace Medical Concepts, Inc's CEO-to-median employee pay ratio was 35:1.
How did shareholders vote on Treace Medical Concepts, Inc's executive compensation?
As disclosed, 95% of shareholders supported Treace Medical Concepts, Inc's executive compensation in the latest say-on-pay vote.
How much does Treace Medical Concepts, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Treace Medical Concepts, Inc reported total board compensation of $1,655,231 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Treace | $755,353 | $0 | $4,635,000 | $0 | $0 | $0 | $14,837 | $5,405,190 |
| Chief Executive Officer, Founder and Board Chair | ||||||||
| Mark Hair | 509,959 | 0 | 4,632,250 | 0 | 0 | 0 | 14,837 | 5,157,046 |
| Chief Financial Officer | ||||||||
| Sean Scanlan | 446,370 | 0 | 1,849,688 | 0 | 0 | 0 | 14,837 | 2,310,894 |
| Chief Innovation Officer | ||||||||
| Scot Elder | 432,096 | 0 | 1,677,050 | 0 | 0 | 0 | 14,837 | 2,123,983 |
| Chief Legal & Compliance Officer, Corporate Secretary | ||||||||
| Gaetano Guglielmino | 440,000 | 0 | 0 | 0 | 0 | 0 | 28,536 | 468,536 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Treace | $5,405,190 | $6,597,160 | $8,422,635 | ↓ −1,191,970 |
| Mark Hair | 5,157,046 | 4,485,302 | 4,686,509 | ↑ +671,744 |
| Sean Scanlan | 2,310,894 | 3,085,435 | 2,949,878 | ↓ −774,541 |
| Scot Elder | 2,123,983 | 4,550,615 | 3,156,616 | ↓ −2,426,632 |
| Gaetano Guglielmino | 468,536 | 3,230,098 | — | ↓ −2,761,562 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Provide competitive compensation to attract, motivate and retain top talent; Directly and substantially link short-term rewards to measurable corporate and individual performance; and Provide long-term rewards based on creating and sustaining stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scot Elder | PSU | 2025-01-22 | 21,250 | 42,500 | — | 85,000 | $474,725 |
| Mark Hair | RSU | 2025-01-22 | — | — | 187,500 | — | 1,768,125 |
| Mark Hair | PSU | 2025-01-22 | 31,250 | 62,500 | — | 125,000 | 698,125 |
| John T. Treace | PSU | 2025-01-22 | 112,500 | 225,000 | — | 450,000 | 2,513,250 |
| Sean Scanlan | PSU | 2025-01-22 | 23,438 | 46,875 | — | 93,750 | 523,594 |
| Scot Elder | RSU | 2025-01-22 | — | — | 127,500 | — | 1,202,325 |
| John T. Treace | RSU | 2025-01-22 | — | — | 225,000 | — | 2,121,750 |
| Sean Scanlan | RSU | 2025-01-22 | — | — | 140,625 | — | 1,326,094 |
| Mark Hair | PSU | 2025-09-15 | 100,000 | 300,000 | — | — | 2,166,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scot Elder | $1,202,325 | $474,725 | $0 | 28.3% |
| Mark Hair | 1,768,125 | 2,864,125 | 0 | 61.8% |
| John T. Treace | 2,121,750 | 2,513,250 | 0 | 54.2% |
| Sean Scanlan | 1,326,094 | 523,594 | 0 | 28.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Scot Elder | RSU | 718 | — | $1,759 |
| Sean Scanlan | RSU | 850 | — | 2,083 |
| Sean Scanlan | RSU | 1,643 | — | 4,025 |
| Scot Elder | RSU | 1,650 | — | 4,043 |
| Mark Hair | RSU | 2,987 | — | 7,318 |
| Scot Elder | Option | 5,525 | 19.15 | — |
| Sean Scanlan | Option | 5,750 | 22.79 | — |
| Scot Elder | PSU | 7,775 | — | 19,049 |
| Treace | PSU | 10,000 | — | 24,500 |
| Mark Hair | PSU | 10,000 | — | 24,500 |
| Scot Elder | PSU | 10,000 | — | 24,500 |
| Sean Scanlan | PSU | 10,000 | — | 24,500 |
| Gaetano Guglielmino | PSU | 10,000 | — | 24,500 |
| Sean Scanlan | RSU | 11,462 | — | 28,082 |
| Scot Elder | Option | 11,750 | 22.07 | — |
| Sean Scanlan | Option | 12,662 | 19.15 | — |
| Scot Elder | RSU | 13,750 | — | 33,688 |
| Mark Hair | RSU | 22,912 | — | 56,134 |
| Mark Hair | Option | 23,025 | 19.15 | — |
| Gaetano Guglielmino | RSU | 24,750 | — | 60,638 |
| Sean Scanlan | Option | 25,974 | 24.07 | — |
| Scot Elder | PSU | 30,650 | — | 75,093 |
| Scot Elder | Option | 31,150 | 24.07 | — |
| Sean Scanlan | PSU | 32,525 | — | 79,686 |
| Treace | RSU | 41,237 | — | 101,031 |
| Scot Elder | PSU | 42,500 | — | 104,125 |
| Scot Elder | RSU | 45,975 | — | 112,639 |
| Mark Hair | PSU | 46,450 | — | 113,803 |
| Sean Scanlan | PSU | 46,875 | — | 114,844 |
| Sean Scanlan | RSU | 48,768 | — | 119,482 |
| Scot Elder | Option | 51,787 | 13.46 | — |
| Mark Hair | Option | 51,924 | 24.07 | — |
| Sean Scanlan | Option | 54,900 | 13.46 | — |
| Treace | Option | 60,141 | 19.15 | — |
| Mark Hair | PSU | 62,500 | — | 153,125 |
| Mark Hair | RSU | 69,656 | — | 170,657 |
| Mark Hair | Option | 78,450 | 13.46 | — |
| Sean Scanlan | RSU | 80,600 | — | 197,470 |
| Scot Elder | RSU | 86,360 | — | 211,582 |
| Treace | Option | 93,450 | 24.07 | — |
| Scot Elder | RSU | 127,500 | — | 312,375 |
| Scot Elder | RSU | 133,333 | — | 326,666 |
| Treace | RSU | 133,743 | — | 327,670 |
| Mark Hair | RSU | 138,173 | — | 338,524 |
| Sean Scanlan | RSU | 140,625 | — | 344,531 |
| Treace | PSU | 178,325 | — | 436,896 |
| Mark Hair | RSU | 187,500 | — | 459,375 |
| Treace | RSU | 225,000 | — | 551,250 |
| Treace | PSU | 225,000 | — | 551,250 |
| Sean Scanlan | RSU | 247,500 | — | 606,375 |
| Mark Hair | PSU | 300,000 | — | 735,000 |
| Scot Elder | PSU | 300,000 | — | 735,000 |
| Scot Elder | RSU | 652,500 | — | 1,936,017 |
| Gaetano Guglielmino | RSU | 660,000 | — | 667,013 |
| Sean Scanlan | RSU | 675,000 | — | 890,203 |
| Mark Hair | RSU | 845,625 | — | 2,033,936 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard W. MottIndependent · Compensation · Nominating/Governance · Departed during FY | $93,029 | $160,005 | $0 | $0 | $0 | $253,034 |
| John K. BakewellIndependent · Lead Independent Director · Audit (Chair) | 77,174 | 160,005 | 0 | 0 | 0 | 237,179 |
| Deepti JainIndependent · Audit · Nominating/Governance (Chair) | 75,000 | 160,005 | 0 | 0 | 0 | 235,005 |
| Lawrence W. HamiltonIndependent · Audit · Compensation (Chair) | 75,000 | 160,005 | 0 | 0 | 0 | 235,005 |
| Elizabeth S. HannaIndependent · Compensation | 65,000 | 160,005 | 0 | 0 | 0 | 225,005 |
| Lance A. BerryIndependent · Audit | 55,000 | 160,005 | 0 | 0 | 0 | 215,005 |
| Jane E. KiernanIndependent · Compensation | 55,000 | 160,005 | 0 | 0 | 0 | 215,005 |
| James T. TreaceIndependent · Nominating/Governance · Not standing for re-election · Departed during FY | 39,993 | — | 0 | 0 | 0 | 39,993 |
| John T. TreaceEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $160,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | 3x Board Cash Retainer (excluding committee/leadership fees) |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $535,196 |
| Equity awards (grant-date value) | $1,120,035 |
| All other compensation | $0 |
| Total cost of the board | $1,655,231 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Treace Medical Concepts as a peer
Companies that benchmark against TMCI
6 companies name TMCI as a compensation peer
- ANGIODYNAMICS INCANGOFY2026
- Axogen, Inc.AXGNFY2025
- Inogen IncINGNFY2025
- Outset Medical, Inc.OMFY2025
- SI-BONE, Inc.SIBNFY2025
- Sight Sciences, Inc.SGHTFY2025
Each company listed discloses TMCI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TMCI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
TMDX TransMedics GroupATEC Alphatec HoldingsLMAT LeMaitre VascularSTAA STAAR Surgical CompanyCSTL Castle BiosciencesTCMD Tactile Systems TechnologyPRCT PROCEPT BioRoboticsSILK Silk Road Medical
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Procept BioRobotics | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | Silk Road Medical | 2023 | Chas McKhann | 105,871 | 13,123,059 | 0 | 93,275 | 13,423,834 |
| 3 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 4 | Alphatec Holdings | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 5 | Staar Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 6 | Castle Biosciences | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 7 | Treace Medical Concepts, Inc | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 8 | LeMaitre Vascular | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 9 | Tactile Systems Technology | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Treace Medical Concepts, Inc | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Alphatec Holdings | 157% | PSU 50 · RSU 50 | No | Compensia |
| Castle Biosciences | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| LeMaitre Vascular | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| Procept BioRobotics | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Silk Road Medical | not disclosed | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
| Staar Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tactile Systems Technology | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 32,785,505 | 1,724,383 | 115,242 | 95% | Passed |
| 2025 | 2025-05-20 | 39,922,580 | 2,315,848 | 15,474 | 94.52% | Passed |
| 2024 | 2024-05-21 | 44,766,561 | 4,009,999 | 13,924 | 91.78% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-19 | 95%a |
| 2025 | 2025-05-20 | 94.52%b |
| 2024 | 2024-05-21 | 91.78%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $5,405,190 |
| Median employee compensation | $153,425 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark Hair | Chief Financial Officer | 2026-04-17 | D | 11,547 | $0 | $0 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-12 | A | 43,000 | 2 | 93,478 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-13 | A | 49,013 | 2 | 120,533 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-14 | A | 61,750 | 3 | 161,495 | Common | Form 4 ↗ |
| Jane E. Kiernan | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence W. Hamilton | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Lance A. Berry | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| John K. Bakewell | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth S. Hanna | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Deepti Jain | Director | 2026-05-19 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-26 | A | 4,508 | 3 | 12,576 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-27 | A | 49,810 | 3 | 143,189 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-05-28 | A | 61,202 | 3 | 184,824 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-06-01 | A | 50,000 | 4 | 177,915 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-06-10 | A | 29,430 | 4 | 118,426 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-06-10 | A | 14,715 | 4 | 59,213 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-06-11 | A | 22,887 | 4 | 92,541 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-06-11 | A | 9,891 | 4 | 39,982 | Common | Form 4 ↗ |
| Mark Hair | Chief Financial Officer | 2026-08-09 | D | 37,102 | 0 | 0 | Common | Form 4 ↗ |
| Scot Elder | Chief Legl & Comp Off, CorpSec | 2026-08-09 | D | 16,253 | 0 | 0 | Common | Form 4 ↗ |
| Sean Scanlan | Chief Innovation Officer | 2026-08-09 | D | 9,814 | 0 | 0 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-08-20 | A | 39,944 | 4 | 177,176 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-08-21 | A | 5,000 | 4 | 21,748 | Common | Form 4 ↗ |
| John T. Treace | Director | 2026-08-24 | A | 11,000 | 4 | 47,731 | Common | Form 4 ↗ |
| Scot Elder | Chief Legl & Comp Off, CorpSec | 2026-09-30 | D | 25,457 | 0 | 0 | Common | Form 4 ↗ |
| Sean Scanlan | Chief Innovation Officer | 2026-10-24 | D | 207 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (65 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Treace. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 41. As printed: 5,405,190. View filing ↗
- Section 01, Mark Hair. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table”. As printed: 5,157,046. View filing ↗
- Section 01, Sean Scanlan. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table”. As printed: 2,310,894. View filing ↗
- Section 01, Scot Elder. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table”. As printed: 2,123,983. View filing ↗
- Section 01, Gaetano Guglielmino. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table”. As printed: 468,536. View filing ↗
- Section 03, Scot Elder PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Hair RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Hair PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John T. Treace PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sean Scanlan PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scot Elder RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John T. Treace RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sean Scanlan RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Hair PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
- Section 08, Richard W. Mott. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 253,034. View filing ↗
- Section 08, John K. Bakewell. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 237,179. View filing ↗
- Section 08, Deepti Jain. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 235,005. View filing ↗
- Section 08, Lawrence W. Hamilton. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 235,005. View filing ↗
- Section 08, Elizabeth S. Hanna. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 225,005. View filing ↗
- Section 08, Lance A. Berry. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 215,005. View filing ↗
- Section 08, Jane E. Kiernan. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 215,005. View filing ↗
- Section 08, James T. Treace. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 39,993. View filing ↗
- Section 08, John T. Treace. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Mark Hair 2026-04-17. Form 4, filed 2026-04-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-14. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane E. Kiernan 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence W. Hamilton 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lance A. Berry 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John K. Bakewell 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth S. Hanna 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepti Jain 2026-05-19. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-05-28. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-06-01. Form 4, filed 2026-06-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-06-11. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Hair 2026-08-09. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scot Elder 2026-08-09. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Scanlan 2026-08-09. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John T. Treace 2026-08-24. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scot Elder 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Scanlan 2026-10-24. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-20. Item 5.07 · say-on-pay result. As reported: 95% (votes for as printed: 32,785,505). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-21. Item 5.07 · say-on-pay result. As reported: 94.52% (votes for as printed: 39,922,580). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-22. Item 5.07 · say-on-pay result. As reported: 91.78% (votes for as printed: 44,766,561). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 535,196 + equity 1,120,035 + all other 0 = 1,655,231, summed across the director compensation table rows.
- Procept BioRobotics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics's own proxy. As printed: 16,783,853. View filing ↗
- Silk Road Medical, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. View filing ↗
- TransMedics Group, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. View filing ↗
- Alphatec Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings's own proxy. As printed: 10,260,507. View filing ↗
- Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
- Castle Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Castle Biosciences's own proxy. As printed: 6,786,771. View filing ↗
- Treace Medical Concepts, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Treace Medical Concepts, Inc's own proxy. As printed: 5,405,190. View filing ↗
- LeMaitre Vascular, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. View filing ↗
- Tactile Systems Technology, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology's own proxy. As printed: 3,466,916. View filing ↗